TSX open
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Get 200 free trades when you open an eligible CIBC Investor's Edge account.

  • ✓200 free stock & ETF trades
  • ✓Unlimited commission-free trades on 180+ select ETFs
  • ✓Offer ends September 30, 2026
Stocks/NASDAQ/TVTX

Travere Therapeutics Inc (TVTX : NASDAQ)

Common Stock

$61.57

USD

+2.13 (3.58%)

Last updated: 2026-09-28

Follow TVTX

TVTX

Travere Therapeutics Inc

Source:WealthAwesomeWealthAwesome
↓ $1.96 (-3.09%)
30 day period
$59.44$63.48$67.52Aug 17Sep 8Sep 28

Performance

1 Day

+3.58%

1 Week

-2.05%

1 Month

-6.24%

YTD

+13.72%

Key Statistics

Market Cap

$5.53B

52W High

$68.73

52W Low

$22.59

P/E Ratio

-

50 Day MA

$61.92

200 Day MA

$44.27

Beta

1.06

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↓Below 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
9/28/2026$59.05$61.75$58.71$61.57$61.571,217,266
9/25/2026$60.89$60.89$59.05$59.44$59.441,205,900
9/24/2026$60.00$60.80$59.22$60.62$60.621,756,270
9/23/2026$60.39$60.89$58.32$59.83$59.831,713,829
9/22/2026$60.37$62.45$59.30$60.28$60.283,120,226
9/21/2026$63.01$63.64$61.85$62.86$62.861,583,778
9/18/2026$64.89$64.89$62.47$62.76$62.762,235,800
9/17/2026$64.51$65.86$63.84$64.74$64.741,384,693
9/16/2026$62.58$64.07$62.41$63.48$63.482,218,321
9/15/2026$65.31$65.32$61.40$62.51$62.512,097,801

Analyst Price Targets

Based on 15 analysts covering TVTX · as of Sep 25, 2026

📈

Wall Street analysts forecast TVTX stock price to rise 22.2% over the next 12 months.

Consensus

Strong Buy

4.60 / 5.00

Avg. Target

US$75.21

+22.2% Upside

Previously US$74.21 on Sep 17, 2026

Current Price

US$61.57

Last close

Analyst Breakdown (15 analysts)

Strong Buy 11
Buy 2
Hold 2
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on TVTX's historical volatility

HistoricalForecast68%95%
US$44.32US$57.09US$69.86US$82.63US$95.40US$108.17TodayJun 17Aug 7Sep 28Nov 10Dec 24Feb 5

30-Day Vol

34.8%

Annualized

90-Day Vol

37.2%

Annualized

Trend (90d)

+33.0%

Annualized drift

90d Mean

US$69.27

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$64.04US$56.79 – US$72.21
60 trading daysUS$66.60US$56.19 – US$78.93
90 trading daysUS$69.27US$56.25 – US$85.29

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Financials

Revenue (TTM)
$591.33M
EBITDA
$22.91M
Profit Margin
-7.35%
ROE (TTM)
-236.36%
EPS (Diluted)
-0.73
Book Value
0.26

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About TVTX.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
DCXDigital Currency X Technology Inc.$6.17+12491.84%
DLXYDelixy Holdings Limited Ordinary Shares$2.44+12100.00%
CTNTCheetah Net Supply Chain Service Inc. Class A Common Stock$3.60+11150.00%
GMEXGMEX ROBOTICS CORPORATION$3.24+7880.30%
IFRXInflaRx N.V.$150.00+7836.51%
FBGLFBS Global Limited Ordinary Shares$4.30+1019.79%
KODKodiak Sciences Inc$89.92+177.96%
LFCRLifecore Biomedical Inc.$6.52+55.24%

TVTX.US news timeline

1 article covering TVTX.US, most recent first

Latest

Why Travere Therapeutics Inc stock is sliding today

•Stocks

Advertisement